SNORA71D: A Potential Drug Target and Biomarker (G677840)

Target Name: SNORA71D

NCBI ID: G677840

SNORA71D

Other Name(s): U71d | small nucleolar RNA, H/ACA box 71D | Small nucleolar RNA, H/ACA box 71D

SNORA71D: A Potential Drug Target and Biomarker

SNORA71D (U71d) is a protein that is expressed in various tissues of the body, including the brain, pancreas, and muscle. Its full name is snake/striated nuclear RNA-binding protein 71D, and it is a member of the nucleic acid-binding proteins (NABPs) family.

SNORA71D is well-known for its ability to bind to specific DNA sequences, both in the coding regions of genes and in non-coding regions of RNA. This ability makes it an attractive candidate for drug targeting, as drugs can be designed to specifically interact with SNORA71D and disrupt its function.

In addition to its potential as a drug target, SNORA71D is also a potential biomarker for various diseases. For example, altered levels of SNORA71D have been observed in the brains of individuals with Alzheimer's disease, and SNORA71D has been suggested as a potential therapeutic target for this disease.

Furthermore, SNORA71D has also been shown to play a role in the regulation of various cellular processes, including cell signaling, cell growth, and apoptosis.

Overall, SNORA71D is a protein that has significant potential as a drug target and biomarker. Further research is needed to fully understand its role in various biological processes and to develop effective treatments.

Protein Name: Small Nucleolar RNA, H/ACA Box 71D

The "SNORA71D Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORA71D comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets